The Obama administration isn't backing down from implementing the second phase of a competitive bidding program that will save Medicare billions of dollars on purchases of medical equipment like wheelchairs and diabetes testing devices.
Victoria Bogatyrenko of United HealthCare, Niall Brennan of CMS, Robin Gelburd of FAIR Health, Jerry Kominski of the University of California-Los Angeles' Center for Health Policy Research and Jeffrey Rice of the Healthcare Blue Book spoke with...
Next year, some family physicians likely will be using ingestible digital pills to keep track of patient's health, the New York Times' "Bits" reports (Bilton, "Bits", New York Times, 6/23).
Such pills feature an embedded microchip to transmit patient data to health care providers.
Last month, FDA said that it is easing federal oversight of the pills.
FDA said it is amending the Federal Food, Drug and Cosmetic Act -- which gives the agency regulatory authority -- to categorize digital pill technology as a class 2 medical device. Traditionally, new devices are automatically labeled as class 3 devices, which is more restrictive than class 2.
In July 2012, FDA approved Proteus Digital Health's microchip, a silicon wafer that is embedded in an ingestible pill.
The device generates electricity when it makes contact with the stomach's digestive fluids and sends a signal to a patch on the patient's skin.
The disposable patch then can transmit information to a health care provider's mobile phone application, including data on:
Time the pill is taken;Heart rate;Body position; andTemperature
In addition to Proteus' digital pill technology, HQ -- a Florida company -- has developed a pill that has a built-in battery and sends real-time body temperature updates as it moves through a patient's body.
Meanwhile, Regina Dugan -- senior vice president for Motorola Mobility's advanced technology and projects group -- at a digital technology conference last month showed an example of a digital pill that can wirelessly communicate with a smartphone application ("Bits", New York Times, 6/23).
An oral fixed-dose therapy to treat venous thromboembolism (VTE) demonstrated noninferiority to treatment with a combination of subcutaneous and oral drugs, investigators in a large multinational tria...
I was once asked, at a journalism conference, how I defined my job. I said: My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself.
California-based SIRUM -- or Supporting Initiatives to Redistribute Unused Medicine -- is leveraging technology to collect unused prescription drugs from nursing homes and match them to low-cost and no-cost clinics that need the medication.
A poll released by the Pew Research Center and the California HealthCare Foundation finds that although most U.S. caregivers search the Internet for health information, few use online tools and applications to track patient care.